instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alanine aminotransferase increased'. | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | TOCILIZUMAB | DrugsGivenReaction | CC BY | 33629921 | 19,002,940 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood fibrinogen decreased'. | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | TOCILIZUMAB | DrugsGivenReaction | CC BY | 33629921 | 19,002,940 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutrophil count decreased'. | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | TOCILIZUMAB | DrugsGivenReaction | CC BY | 33629921 | 19,002,940 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'White blood cell count decreased'. | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | TOCILIZUMAB | DrugsGivenReaction | CC BY | 33629921 | 19,002,940 | 2021-12 |
What was the administration route of drug 'TOCILIZUMAB'? | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33629921 | 19,002,940 | 2021-12 |
What was the outcome of reaction 'Alanine aminotransferase increased'? | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | Recovered | ReactionOutcome | CC BY | 33629921 | 19,002,940 | 2021-12 |
What was the outcome of reaction 'Blood fibrinogen decreased'? | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | Recovered | ReactionOutcome | CC BY | 33629921 | 19,002,940 | 2021-12 |
What was the outcome of reaction 'Neutrophil count decreased'? | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | Recovered | ReactionOutcome | CC BY | 33629921 | 19,002,940 | 2021-12 |
What was the outcome of reaction 'White blood cell count decreased'? | A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects.
QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S ... | Recovered | ReactionOutcome | CC BY | 33629921 | 19,002,940 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abortion spontaneous'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,052 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abortion'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,093 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atrioventricular septal defect'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,387 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Craniofacial deformity'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,022,419 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exposure during pregnancy'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,052 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Foetal exposure during pregnancy'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,387 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypospadias'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,243 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lissencephaly'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,185 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Meningomyelocele'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,181 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Polydactyly'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,263 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Talipes'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,260 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ventricular septal defect'. | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | METOCLOPRAMIDE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33631840 | 19,020,175 | 2021-05 |
What was the administration route of drug 'METOCLOPRAMIDE HYDROCHLORIDE'? | Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.
OBJECTIVE
To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.
METHODS
Pregnancy outcome data were obtained for women at two Japanese facilities that ... | Transplacental | DrugAdministrationRoute | CC BY-NC-ND | 33631840 | 19,020,387 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anterior chamber flare'. | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blindness'. | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33631912 | 19,085,908 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eye inflammation'. | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vision blurred'. | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Visual acuity reduced'. | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vitreous opacities'. | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33631912 | 19,247,775 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vitritis'. | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
What was the administration route of drug 'AFLIBERCEPT'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Intraocular | DrugAdministrationRoute | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
What was the outcome of reaction 'Anterior chamber flare'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Recovered | ReactionOutcome | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
What was the outcome of reaction 'Blindness'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Recovered | ReactionOutcome | CC BY | 33631912 | 19,085,908 | 2021-02-25 |
What was the outcome of reaction 'Eye inflammation'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Recovered | ReactionOutcome | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
What was the outcome of reaction 'Vision blurred'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Recovered | ReactionOutcome | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
What was the outcome of reaction 'Visual acuity reduced'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Recovered | ReactionOutcome | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
What was the outcome of reaction 'Vitreous opacities'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Recovered | ReactionOutcome | CC BY | 33631912 | 19,247,775 | 2021-02-25 |
What was the outcome of reaction 'Vitritis'? | Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the ... | Recovered | ReactionOutcome | CC BY | 33631912 | 19,243,928 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse event'. | Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
BACKGROUND
The benefits of adjuvant chemotherapy for elderly patients with gastric cancer (GC) remain unknown because elderly patie... | CAPECITABINE | DrugsGivenReaction | CC BY | 33632161 | 18,987,167 | 2021-02-25 |
What was the administration route of drug 'CAPECITABINE'? | Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
BACKGROUND
The benefits of adjuvant chemotherapy for elderly patients with gastric cancer (GC) remain unknown because elderly patie... | Oral | DrugAdministrationRoute | CC BY | 33632161 | 18,987,167 | 2021-02-25 |
What was the dosage of drug 'CAPECITABINE'? | Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
BACKGROUND
The benefits of adjuvant chemotherapy for elderly patients with gastric cancer (GC) remain unknown because elderly patie... | TWICE DAILY ON DAYS 1 TO 14 OF EACH CYCLE | DrugDosageText | CC BY | 33632161 | 18,987,167 | 2021-02-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Keratitis fungal'. | Keratitis by Scopulariopsis brevicaulis Fungus After LASIK - A Case Report.
To describe a rare case of an interface filamentous fungal keratitis and its successful clinical approach and management.
Retrospective case report. Analysis of the patient's clinical records.
A healthy 30-year-old woman presenting with complai... | DEXAMETHASONE SODIUM PHOSPHATE, PREDNISOLONE, TRIAMCINOLONE | DrugsGivenReaction | CC BY-NC | 33633469 | 19,950,282 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Scopulariopsis infection'. | Keratitis by Scopulariopsis brevicaulis Fungus After LASIK - A Case Report.
To describe a rare case of an interface filamentous fungal keratitis and its successful clinical approach and management.
Retrospective case report. Analysis of the patient's clinical records.
A healthy 30-year-old woman presenting with complai... | DEXAMETHASONE SODIUM PHOSPHATE, PREDNISOLONE, TRIAMCINOLONE | DrugsGivenReaction | CC BY-NC | 33633469 | 19,950,282 | 2021 |
What was the administration route of drug 'PREDNISOLONE'? | Keratitis by Scopulariopsis brevicaulis Fungus After LASIK - A Case Report.
To describe a rare case of an interface filamentous fungal keratitis and its successful clinical approach and management.
Retrospective case report. Analysis of the patient's clinical records.
A healthy 30-year-old woman presenting with complai... | Oral | DrugAdministrationRoute | CC BY-NC | 33633469 | 19,950,282 | 2021 |
What was the administration route of drug 'TRIAMCINOLONE'? | Keratitis by Scopulariopsis brevicaulis Fungus After LASIK - A Case Report.
To describe a rare case of an interface filamentous fungal keratitis and its successful clinical approach and management.
Retrospective case report. Analysis of the patient's clinical records.
A healthy 30-year-old woman presenting with complai... | Sunconjunctival | DrugAdministrationRoute | CC BY-NC | 33633469 | 19,950,282 | 2021 |
What was the dosage of drug 'TRIAMCINOLONE'? | Keratitis by Scopulariopsis brevicaulis Fungus After LASIK - A Case Report.
To describe a rare case of an interface filamentous fungal keratitis and its successful clinical approach and management.
Retrospective case report. Analysis of the patient's clinical records.
A healthy 30-year-old woman presenting with complai... | TWO INJECTIONS WERE ADMINISTERED ON TWO CONSECUTIVE DAYS (DAY 15 AND 16) AND THIRD INJECTION WAS ADM | DrugDosageText | CC BY-NC | 33633469 | 19,950,282 | 2021 |
What was the outcome of reaction 'Keratitis fungal'? | Keratitis by Scopulariopsis brevicaulis Fungus After LASIK - A Case Report.
To describe a rare case of an interface filamentous fungal keratitis and its successful clinical approach and management.
Retrospective case report. Analysis of the patient's clinical records.
A healthy 30-year-old woman presenting with complai... | Recovered | ReactionOutcome | CC BY-NC | 33633469 | 19,950,282 | 2021 |
What was the outcome of reaction 'Scopulariopsis infection'? | Keratitis by Scopulariopsis brevicaulis Fungus After LASIK - A Case Report.
To describe a rare case of an interface filamentous fungal keratitis and its successful clinical approach and management.
Retrospective case report. Analysis of the patient's clinical records.
A healthy 30-year-old woman presenting with complai... | Recovered | ReactionOutcome | CC BY-NC | 33633469 | 19,950,282 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Case Report: Late-Onset Temporal Lobe Epilepsy Following Subarachnoid Hemorrhage: An Interplay Between Pre-existing Cortical Development Abnormality and Tissue Damage.
Epileptogenicity following brain insult depends on various factors including severity of the resulting lesion and extent of brain damage. We report a 54... | LAMOTRIGINE, LEVETIRACETAM, VALPROIC ACID, ZONISAMIDE | DrugsGivenReaction | CC BY | 33633663 | 20,672,527 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Case Report: Late-Onset Temporal Lobe Epilepsy Following Subarachnoid Hemorrhage: An Interplay Between Pre-existing Cortical Development Abnormality and Tissue Damage.
Epileptogenicity following brain insult depends on various factors including severity of the resulting lesion and extent of brain damage. We report a 54... | LAMOTRIGINE, LEVETIRACETAM, VALPROIC ACID, ZONISAMIDE | DrugsGivenReaction | CC BY | 33633663 | 20,681,904 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthritis'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,074,033 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Conjunctivitis'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,074,234 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Liver disorder'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,074,441 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ocular ischaemic syndrome'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,074,441 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,074,441 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonitis'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,078,861 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Retinal melanoma'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,078,861 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin disorder'. | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 33633802 | 19,074,013 | 2021 |
What was the outcome of reaction 'Conjunctivitis'? | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | Not recovered | ReactionOutcome | CC BY-NC | 33633802 | 19,074,234 | 2021 |
What was the outcome of reaction 'Ocular ischaemic syndrome'? | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | Recovered | ReactionOutcome | CC BY-NC | 33633802 | 19,074,441 | 2021 |
What was the outcome of reaction 'Retinal melanoma'? | Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition ... | Not recovered | ReactionOutcome | CC BY-NC | 33633802 | 19,078,861 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Twelve Drummers Drumming… With Dystonia.
Reports of drummers' dystonia are rare, particularly compared to the literature on dystonia in string, piano and brass players. Several cases of drummers' dystonia have been included in large series of multiple instrumentalists, but there are few reports comprised exclusively of... | CARBIDOPA\LEVODOPA | DrugsGivenReaction | CC BY | 33633869 | 19,141,165 | 2021-02-08 |
What was the administration route of drug 'CARBIDOPA\LEVODOPA'? | Twelve Drummers Drumming… With Dystonia.
Reports of drummers' dystonia are rare, particularly compared to the literature on dystonia in string, piano and brass players. Several cases of drummers' dystonia have been included in large series of multiple instrumentalists, but there are few reports comprised exclusively of... | Oral | DrugAdministrationRoute | CC BY | 33633869 | 19,141,165 | 2021-02-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blindness'. | An Uncommon Aflibercept Side Effect: Full Thickness Macular Hole Formation After Intravitreal Injections in Patients With Pre-existing Vitreomacular Traction.
Aflibercept is an intravitreally injected anti-vascular endothelial growth factor, commonly used in patients with several retinal pathologies, including neovascu... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33633901 | 18,945,478 | 2021-01-23 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Macular hole'. | An Uncommon Aflibercept Side Effect: Full Thickness Macular Hole Formation After Intravitreal Injections in Patients With Pre-existing Vitreomacular Traction.
Aflibercept is an intravitreally injected anti-vascular endothelial growth factor, commonly used in patients with several retinal pathologies, including neovascu... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 33633901 | 18,945,478 | 2021-01-23 |
What was the administration route of drug 'AFLIBERCEPT'? | An Uncommon Aflibercept Side Effect: Full Thickness Macular Hole Formation After Intravitreal Injections in Patients With Pre-existing Vitreomacular Traction.
Aflibercept is an intravitreally injected anti-vascular endothelial growth factor, commonly used in patients with several retinal pathologies, including neovascu... | Intraocular | DrugAdministrationRoute | CC BY | 33633901 | 18,945,478 | 2021-01-23 |
What was the outcome of reaction 'Blindness'? | An Uncommon Aflibercept Side Effect: Full Thickness Macular Hole Formation After Intravitreal Injections in Patients With Pre-existing Vitreomacular Traction.
Aflibercept is an intravitreally injected anti-vascular endothelial growth factor, commonly used in patients with several retinal pathologies, including neovascu... | Recovering | ReactionOutcome | CC BY | 33633901 | 18,945,478 | 2021-01-23 |
What was the outcome of reaction 'Macular hole'? | An Uncommon Aflibercept Side Effect: Full Thickness Macular Hole Formation After Intravitreal Injections in Patients With Pre-existing Vitreomacular Traction.
Aflibercept is an intravitreally injected anti-vascular endothelial growth factor, commonly used in patients with several retinal pathologies, including neovascu... | Recovered | ReactionOutcome | CC BY | 33633901 | 18,945,480 | 2021-01-23 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Depressed mood'. | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | ASPIRIN, ATORVASTATIN, CARVEDILOL, CLOPIDOGREL BISULFATE, DEUTETRABENAZINE, DOCUSATE, HYDRALAZINE HYDROCHLORIDE, LEVOTHYROXINE, NIFEDIPINE, QUETIAPINE | DrugsGivenReaction | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Overdose'. | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | ASPIRIN, ATORVASTATIN, CARVEDILOL, CLOPIDOGREL BISULFATE, DEUTETRABENAZINE, DOCUSATE, HYDRALAZINE HYDROCHLORIDE, LEVOTHYROXINE, NIFEDIPINE, QUETIAPINE | DrugsGivenReaction | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Somnolence'. | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | ASPIRIN, ATORVASTATIN, CARVEDILOL, CLOPIDOGREL BISULFATE, DEUTETRABENAZINE, DOCUSATE, HYDRALAZINE HYDROCHLORIDE, LEVOTHYROXINE, NIFEDIPINE, QUETIAPINE | DrugsGivenReaction | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'ASPIRIN'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'ATORVASTATIN'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'CARVEDILOL'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'CLOPIDOGREL BISULFATE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'DEUTETRABENAZINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'DOCUSATE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'HYDRALAZINE HYDROCHLORIDE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'LEVOTHYROXINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'NIFEDIPINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the administration route of drug 'QUETIAPINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | Oral | DrugAdministrationRoute | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the dosage of drug 'ASPIRIN'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | 81 MILLIGRAM DAILY; | DrugDosageText | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the dosage of drug 'ATORVASTATIN'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | 40 MILLIGRAM DAILY; | DrugDosageText | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the dosage of drug 'CLOPIDOGREL BISULFATE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | 75 MILLIGRAM DAILY; | DrugDosageText | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the dosage of drug 'DEUTETRABENAZINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | 12 MILLIGRAM DAILY; | DrugDosageText | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the dosage of drug 'LEVOTHYROXINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | 125 MICROGRAM DAILY; | DrugDosageText | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the dosage of drug 'NIFEDIPINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | 90 MILLIGRAM DAILY; | DrugDosageText | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
What was the dosage of drug 'QUETIAPINE'? | Benign Presentation Following Massive Deutetrabenazine Overdose.
Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive d... | 50 MILLIGRAM DAILY; BEFORE BED | DrugDosageText | CC BY | 33633914 | 18,962,515 | 2021-01-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Glomerulonephritis membranous'. | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | HYDROCHLOROTHIAZIDE, OLMESARTAN | DrugsGivenReaction | CC BY | 33633925 | 19,326,783 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoalbuminaemia'. | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | HEPARIN SODIUM, HYDROCHLOROTHIAZIDE, IBUPROFEN, LENZILUMAB, METHYLPREDNISOLONE, OLMESARTAN | DrugsGivenReaction | CC BY | 33633925 | 19,483,859 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | HEPARIN SODIUM, HYDROCHLOROTHIAZIDE, IBUPROFEN, LENZILUMAB, METHYLPREDNISOLONE, OLMESARTAN | DrugsGivenReaction | CC BY | 33633925 | 19,483,859 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Proteinuria'. | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | HYDROCHLOROTHIAZIDE, IBUPROFEN, OLMESARTAN | DrugsGivenReaction | CC BY | 33633925 | 19,275,153 | 2021 |
What was the administration route of drug 'HEPARIN SODIUM'? | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | Other | DrugAdministrationRoute | CC BY | 33633925 | 19,483,859 | 2021 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33633925 | 19,483,859 | 2021 |
What was the outcome of reaction 'Acute kidney injury'? | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | Recovering | ReactionOutcome | CC BY | 33633925 | 19,275,153 | 2021 |
What was the outcome of reaction 'Proteinuria'? | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | Recovering | ReactionOutcome | CC BY | 33633925 | 19,275,153 | 2021 |
What was the outcome of reaction 'Renal tubular injury'? | Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.
BACKGROUND
Though respiratory, immune, and coagulation systems are major targets of coronavirus disease 2019 (COVID-19), kidney dysfunction, presenting with acute kidney injury (AKI), is also common. Most AKI cases in COVID-19 ... | Recovering | ReactionOutcome | CC BY | 33633925 | 19,275,153 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypersensitivity'. | Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe.
We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 ... | DACLATASVIR DIHYDROCHLORIDE, SOFOSBUVIR | DrugsGivenReaction | CC BY-NC-ND | 33634203 | 19,405,338 | 2021-02 |
What was the outcome of reaction 'Hypersensitivity'? | Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe.
We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33634203 | 19,405,338 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | Acute heart transplantation from mechanical circulatory support in a human immunodeficiency virus-positive patient with fulminant myocarditis.
Since the establishment of highly active antiretroviral therapy, survival rates have improved among patients with human immunodeficiency virus infection giving them the possibil... | COBICISTAT\DARUNAVIR ETHANOLATE, ETRAVIRINE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 33634606 | 19,973,241 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immunosuppressant drug level increased'. | Acute heart transplantation from mechanical circulatory support in a human immunodeficiency virus-positive patient with fulminant myocarditis.
Since the establishment of highly active antiretroviral therapy, survival rates have improved among patients with human immunodeficiency virus infection giving them the possibil... | COBICISTAT\DARUNAVIR ETHANOLATE, ETRAVIRINE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 33634606 | 19,973,241 | 2021-04 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.